HGF/c-MET抑制剂治疗非小细胞肺癌的研究进展

被引：27

作者：

蒋涛

周彩存

机构：

[1] 上海市肺科医院

来源：

中国肺癌杂志 | 2015年 / 04期

关键词：

HGF; c-MET; 肺肿瘤; 抑制剂;

D O I：

暂无

中图分类号：

R734.2 [肺肿瘤];

学科分类号：

100117 [系统生物医学];

摘要：

分子靶向治疗在晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的治疗中起着越来越重要的作用。肝细胞生长因子/c-MET(hepatocyte growth factor/c-MET,HGF/c-MET)信号通路在NSCLC的发生、发展及NSCLC患者对表皮生长因子受体抑制剂(epidermal growth factor receptor tyrosine kinase inhibitor,EGFR-TKI)的耐药方面都起着重要的作用,其已经成为NSCLC分子靶向治疗的又一热点。c-MET扩增或过表达被认为可能是继EGFR和间变淋巴瘤激酶(anaplastic lymphoma kinase,ALK)融合基因之后,NSCLC又一特征性的基因突变。HGF/c-MET抑制剂也在临床前的研究中取得良好的抗肿瘤效果。近期公布的一些II期/III期临床研究的数据显示,HGF/c-MET抑制剂可以使部分c-MET扩增或过表达的NSCLC患者生存获益。因此,本文就HGF/c-MET抑制剂治疗NSCLC的研究进展做一综述。

引用

页码：240 / 244

页数：5

共 6 条

[1]

HGF/c-met system targeting PI3K/AKT and STAT3/phosphorylated-STAT3 pathways in pituitary adenomas: an immunohistochemical characterization in view of targeted therapies[J] Maria Trovato;Maria Luisa Torre;Marta Ragonese;Angela Simone;Rosy Scarfì;Valeria Barresi;Giuseppe Giuffrè;Salvatore Benvenga;Flavio F. Angileri;Giovanni Tuccari;Francesco Trimarchi;Rosaria Maddalena Ruggeri;Salvatore Cannavò Endocrine 2013,

[2]

Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer[J] Manolo D'Arcangelo;Federico Cappuzzo Biologics: Targets and Therapy 2013,

[3]

Rationale and Design of MARQUEE: A Phase III; Randomized; Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic; Nonsquamous; Non–Small-Cell Lung Cancer[J] Giorgio V. Scagliotti;Silvia Novello;Joan H. Schiller;Vera Hirsh;Lecia V. Sequist;Jean-Charles Soria;Joachim von Pawel;Brian Schwartz;Reinhard Von Roemeling;Alan B. Sandler Clinical Lung Cancer 2012,

[4]

Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-Induced EGFR-TKI Resistance in EGFR Mutant Lung Cancer[J] Shinji Takeuchi;Wei Wang;Qi Li;Tadaaki Yamada;Kenji Kita;Ivan S. Donev;Takahiro Nakamura;Kunio Matsumoto;Eiji Shimizu;Yasuhiko Nishioka;Saburo Sone;Takayuki Nakagawa;Toshimitsu Uenaka;Seiji Yano The American Journal of Pathology 2012,

[5]

c-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas[J] Koji Tsuta;Yoshiki Kozu;Takahiro Mimae;Akihiko Yoshida;Takashi Kohno;Ikuo Sekine;Tomohide Tamura;Hisao Asamura;Koh Furuta;Hitoshi Tsuda Journal of Thoracic Oncology 2012,

[6]

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL; CTONG-0802): a multicentre; open-label; randomised; phase 3 study[J] Caicun Zhou;Yi-Long Wu;Gongyan Chen;Jifeng Feng;Xiao-Qing Liu;Changli Wang;Shucai Zhang;Jie Wang;Songwen Zhou;Shengxiang Ren;Shun Lu;Li Zhang;Chengping Hu;Chunhong Hu;Yi Luo;Lei Chen;Ming Ye;Jianan Huang;Xiuyi Zhi;Yiping Zhang;Qingyu Xiu;Jun Ma;Li Zhang;Changxuan You Lancet Oncology 2011,

← 1 →